These observations, combined with the differential effects of CD9 overexpression in prostate cancer cells demonstrated in this study, led us to hypothesise that mortalin distribution in PC-3 and PC-3M-LN4 cells could also differ. The gene discussed is HSPA9; the disease is Familial prostate cancer.